Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)

SEK 3.42

(-2.29%)

Operating Expenses Summary of Newbury Pharmaceuticals AB (publ)

  • Newbury Pharmaceuticals AB (publ)'s latest annual operating expenses in 2024 was 30.11 Million SEK , up 42.26% from previous year.
  • Newbury Pharmaceuticals AB (publ)'s latest quarterly operating expenses in 2024 Q4 was 7.73 Million SEK , down -10.11% from previous quarter.
  • Newbury Pharmaceuticals AB (publ) reported a annual operating expenses of 21.16 Million SEK in annual operating expenses 2023, up 51.81% from previous year.
  • Newbury Pharmaceuticals AB (publ) reported a annual operating expenses of 13.94 Million SEK in annual operating expenses 2022, up 129.27% from previous year.
  • Newbury Pharmaceuticals AB (publ) reported a quarterly operating expenses of 7.46 Million SEK for 2024 Q1, up 102.77% from previous quarter.
  • Newbury Pharmaceuticals AB (publ) reported a quarterly operating expenses of 7.73 Million SEK for 2024 Q4, down -10.11% from previous quarter.

Annual Operating Expenses Chart of Newbury Pharmaceuticals AB (publ) (2024 - 2021)

Historical Annual Operating Expenses of Newbury Pharmaceuticals AB (publ) (2024 - 2021)

Year Operating Expenses Operating Expenses Growth
2024 30.11 Million SEK 42.26%
2023 21.16 Million SEK 51.81%
2022 13.94 Million SEK 129.27%
2021 6.08 Million SEK 0.0%

Peer Operating Expenses Comparison of Newbury Pharmaceuticals AB (publ)

Name Operating Expenses Operating Expenses Difference
AcuCort AB 13.24 Million SEK -127.27%
AlzeCure Pharma AB (publ) 38.26 Million SEK 21.303%
BioGaia AB (publ) 507.08 Million SEK 94.062%
Enzymatica AB (publ) 79.92 Million SEK 62.326%
Enorama Pharma AB (publ) 38.22 Million SEK 21.229%
Gabather AB (publ) 9.47 Million SEK -217.828%
Klaria Pharma Holding AB (publ.) 14.88 Million SEK -102.304%
Moberg Pharma AB (publ) 27.46 Million SEK -9.642%
Nanexa AB (publ) 135.78 Million SEK 77.824%
ODI Pharma AB -5.00 SEK 602220100.0%
Orexo AB (publ) 659.4 Million SEK 95.434%
Probi AB (publ) 208.93 Million SEK 85.588%
Swedencare AB (publ) 1.12 Billion SEK 97.33%
Swedish Orphan Biovitrum AB (publ) 9.39 Billion SEK 99.68%
Toleranzia AB 6.97 Million SEK -331.885%
Vivesto AB 355.71 Million SEK 91.535%